Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Core Insights - Immuneering Corporation is hosting a conference call and live webcast on June 17, 2025, to provide updates on its Phase 2a clinical trial of IMM-1-104 for first-line pancreatic cancer patients [1][2] Company Overview - Immuneering Corporation is a clinical-stage oncology company focused on developing treatments that help patients outlive their disease [3] - The lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK, aimed at improving durability and tolerability while expanding indications to include MAPK pathway-driven tumors, particularly pancreatic cancers [3] - IMM-1-104 is currently undergoing a Phase 2a trial in patients with advanced solid tumors, including pancreatic cancer [3] - The company also has early-stage programs in its development pipeline [3]